Sign in to view content

It’s the Patient, Not the Agent: An Assessment of Anti-VEGF Extended Dosing Intervals in Patients With nAMD

David A. Eichenbaum, MD, FASRS

Video
Published 2019

Related

One Year and Beyond: Results of Phase 1b Study of KSI-301, an AntiVEGF Antibody Biopolymer Conjugate With Extended Durability, in wAMD, DME, and RVO
Mark R. Barakat, MD
Updates from the Field
2020
Ziv-aflibercept Efficacy in Better Regulating Neovascular AMD (ZEBRA) Trial
Kapil G. Kapoor, MD
On Demand Cases, Courses, and Papers
2019
Presumed Silicone Oil Droplets
Rahul N. Khurana, MD, FASRS
Updates from the Field
2017

Category: AMD-Neovascular

See more